Related Experiment Video

Updated: Jul 13, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

A new mutational AKTivation in the PI3K pathway

Joan Brugge1, Mien-Chie Hung, Gordon B Mills

  • 1Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.

Cancer Cell
|August 19, 2007
PubMed

Insights

A novel mutation in the AKT1 gene (E17K) was identified in breast, colorectal, and ovarian cancers. This AKT1 mutation drives cancer growth independently of common PI3K pathway signaling, presenting new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The phosphatidylinositol-3-kinase (PI3K) pathway is crucial in cell signaling and is frequently altered in cancer.
  • While PI3K pathway members are often mutated, functional mutations in AKT isoforms have been rare.
  • AKT is a key signaling node within the PI3K pathway, known for its transforming potential.

Purpose of the Study:

  • To identify functional mutations in AKT isoforms implicated in cancer development.
  • To investigate the mechanism of transformation driven by identified AKT mutations.

Main Methods:

  • Analysis of cancer patient genomic data to identify AKT mutations.
  • Functional assays to assess the transforming activity of mutated AKT.
  • Biochemical studies to elucidate the molecular mechanism of AKT activation.

Main Results:

  • A transforming mutation, E17K in the PH domain of AKT1, was identified in breast (8%), colorectal (6%), and ovarian (2%) cancers.
  • The E17K-AKT1 mutation promotes cancer cell transformation.
  • This transformation is mediated by recruitment of AKT1 to the cell membrane independent of phosphoinositide binding (PtdIns(3,4)P2 and PtdIns(3,4,5)P3).

Conclusions:

  • The E17K mutation in AKT1 represents a novel oncogenic driver in several human cancers.
  • This finding reveals a new mechanism of AKT activation, independent of canonical PI3K pathway signaling.
  • The E17K-AKT1 mutation offers a potential therapeutic target for specific cancer types.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...